Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study

被引:46
|
作者
Nakayama, Masaaki [1 ,2 ]
Sato, Toshinobu [3 ]
Miyazaki, Mariko
Matsushima, Masato [4 ]
Sato, Hiroshi [5 ]
Taguma, Yoshio [3 ]
Ito, Sadayoshi
机构
[1] Tohoku Univ, Grad Sch Med, Ctr Adv Integrated Renal Sci, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Fukushima Med Univ, Sch Med, Fukushima, Japan
[3] Sendai Shakaihoken Hosp, Kidney Ctr, Sendai, Miyagi, Japan
[4] Jikei Univ, Sch Med, Dept Clin Res, Tokyo, Japan
[5] Tohoku Univ, Grad Sch Pharmacol, Dept Clin Pharmacol, Sendai, Miyagi 9808574, Japan
关键词
cardiovascular disease; chronic kidney disease; hypertensive nephropathy; GENERAL JAPANESE POPULATION; GLOMERULAR-FILTRATION-RATE; MECHANISMS; DYSLIPIDEMIA; PATHOGENESIS; PROTEINURIA; CHILDREN; OUTCOMES; STRESS; STROKE;
D O I
10.1038/hr.2011.96
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
To examine the clinical significance of hypertensive nephropathy (HN) among non-diabetic chronic kidney disease (CKD) patients. The study comprised 2692 CKD patients recruited from 11 outpatient nephrology clinics; these included 1306 patients with primary renal disease (PRD), 458 patients with HN, 283 patients with diabetic nephropathy (DN) and 645 patients with other nephropathies (ONs). All patients fulfilled the criteria of CKD, with a persistent low estimated glomerular filtration rate (eGFR) <60 ml min(-1) per 1.73 m(2) or proteinuria as determined by a urine dipstick test. The risk factors for cardiovascular disease (CVD), such as ischemic heart disease, congestive heart failure and stroke; all-cause mortality; and progression to end-stage renal failure (dialysis induction) were analyzed using a Cox proportional hazards model in each group. During a mean follow-up period of 22.6 months from recruitment, 100 patients were lost to follow-up and 192 patients began chronic dialysis therapy. A total of 115 CVD events occurred (stroke in 37 cases), and 44 patients died. Regarding CVD events and death, there were significant differences in the hazard ratios (HRs) for the groups of patients with different underlying renal diseases as determined by both univariate and multivariate analysis adjusted for confounding factors including estimated glomerular filtration rate: PRD, 1.0 (reference); HN, 3.33 (95% confidence interval, 1.82-6.09); DN, 5.93 (2.80-12.52); and ON, 2.22 (1.22-4.05). However, there were no differences in the hazard ratio for dialysis induction for the groups of patients with different underlying renal diseases. HN is associated with an increased risk of CVD events and death among non-diabetic CKD patients, which highlights the clinical significance of HN. Hypertension Research (2011) 34, 1106-1110; doi:10.1038/hr.2011.96; published online 28 July 2011
引用
收藏
页码:1106 / 1110
页数:5
相关论文
共 50 条
  • [41] Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
    Wheeler, David C.
    Stefansson, Bergur, V
    Jongs, Niels
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Toto, Robert D.
    Sjostrom, C. David
    Langkilde, Anna Maria
    Heerspink, Hiddo J. L.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (01) : 22 - 31
  • [42] Non-Diabetic Chronic Kidney Disease Influences Retinal Microvasculature
    Baumann, Marcus
    Schwarz, Sonja
    Kotliar, Konstantin
    von Eynatten, Maximilian
    Trucksaess, Arno Schmidt
    Burkhardt, Klaus
    Lutz, Jens
    Heemann, Uwe
    Lanzl, Ines
    KIDNEY & BLOOD PRESSURE RESEARCH, 2009, 32 (06) : 428 - 433
  • [43] Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study
    Di Angelantonio, Emanuele
    Chowdhury, Rajiv
    Sarwar, Nadeem
    Aspelund, Thor
    Danesh, John
    Gudnason, Vilmundur
    BMJ-BRITISH MEDICAL JOURNAL, 2010, 341 : 768
  • [44] Aliskiren and losartan trial in non-diabetic chronic kidney disease
    Woo, Keng-Thye
    Choong, Hui-Lin
    Wong, Kok-Seng
    Tan, Han-Kim
    Foo, Marjorie
    Fook-Chong, Stephanie
    Lee, Evan J. C.
    Anantharaman, Vathsala
    Lee, Grace S. L.
    Chan, Choong-Meng
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2014, 15 (04) : 515 - 522
  • [45] CVD risk in non-albuminuric chronic kidney disease in hypertensive, non-diabetic subjects: A post-hoc analysis from SPRINT
    Sheng, Chang-Sheng
    Wang, Dan
    Yuan, Jiangzi
    Cheng, Yi
    Sun, Siming
    Yang, Yulin
    Miao, Ya
    Wang, Weiming
    Tian, Jingyan
    Bloomgarden, Zachary T.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [46] Referral to nephrologists for chronic kidney disease care: Is non-diabetic kidney disease ignored?
    Navaneethan, Sankar D.
    Nigwekar, Sagar
    Sengodan, Mohan
    Anand, Edwin
    Kadam, Sarika
    Jeevanantham, Vinodh
    Grieff, Marvin
    Choudhry, Wajid
    NEPHRON CLINICAL PRACTICE, 2007, 106 (03): : 113 - 118
  • [47] Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients
    Bermudez-Lopez, Marcelino
    Perpinan, Hector
    Amigo, Nuria
    Castro, Eva
    Alonso, Nuria
    Mauricio, Didac
    Fernandez, Elvira
    Valdivielso, Jose M.
    CLINICAL KIDNEY JOURNAL, 2021, 14 (12) : 2591 - 2599
  • [48] Chronic Kidney Disease is Associated With Increased Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Arterial Disease
    Westin, Gregory G.
    Armstrong, Ehrin J.
    Chen, Debbie C.
    Laird, John R.
    CIRCULATION, 2014, 130
  • [49] Cardiovascular events and mortality in chronic kidney disease (stages I-IV)
    Quiroga, Borja
    Verdalles, Ursula
    Reque, Javier
    Garcia de Vinuesa, Soledad
    Goicoechea, Marian
    Luno, Jose
    NEFROLOGIA, 2013, 33 (04): : 539 - 545
  • [50] Endothelin antagonists for diabetic and non-diabetic chronic kidney disease
    Kohan, Donald E.
    Pollock, David M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (04) : 573 - 579